- Home
- IMNM vs CINGW Comparison
IMNM vs CINGW Comparison
Compare IMNM & CINGW Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- IMNM
- CINGW
- Stock Information
- Founded
- IMNM 2006
- CINGW N/A
- Country
- IMNM United States
- CINGW United States
- Employees
- IMNM N/A
- CINGW 13
- Industry
- IMNM Medicinal Chemicals and Botanical Products
- CINGW Biotechnology: Pharmaceutical Preparations
- Sector
- IMNM Health Care
- CINGW Health Care
- Exchange
- IMNM Nasdaq
- CINGW Nasdaq
- Market Cap
- IMNM 747.7M
- CINGW N/A
- IPO Year
- IMNM 2020
- CINGW 2021
- Fundamental
- Price
- IMNM $12.30
- CINGW $0.07
- Analyst Decision
- IMNM Strong Buy
- CINGW
- Analyst Count
- IMNM 4
- CINGW 0
- Target Price
- IMNM $28.75
- CINGW N/A
- AVG Volume (30 Days)
- IMNM 859.8K
- CINGW N/A
- Earning Date
- IMNM 11-07-2024
- CINGW N/A
- Dividend Yield
- IMNM N/A
- CINGW N/A
- EPS Growth
- IMNM N/A
- CINGW N/A
- EPS
- IMNM N/A
- CINGW N/A
- Revenue
- IMNM $10,784,000.00
- CINGW N/A
- Revenue This Year
- IMNM N/A
- CINGW N/A
- Revenue Next Year
- IMNM N/A
- CINGW N/A
- P/E Ratio
- IMNM N/A
- CINGW N/A
- Revenue Growth
- IMNM 62.73
- CINGW N/A
- 52 Week Low
- IMNM $6.93
- CINGW N/A
- 52 Week High
- IMNM $30.96
- CINGW N/A
- Technical
- Relative Strength Index (RSI)
- IMNM 35.27
- CINGW N/A
- Support Level
- IMNM $12.24
- CINGW N/A
- Resistance Level
- IMNM $13.40
- CINGW N/A
- Average True Range (ATR)
- IMNM 0.84
- CINGW 0.00
- MACD
- IMNM -0.25
- CINGW 0.00
- Stochastic Oscillator
- IMNM 10.58
- CINGW 0.00
About IMNM Immunome Inc.
Immunome Inc is a biopharmaceutical company. It is engaged in utilizing a proprietary human memory B cell platform to discover and develop first-in-class antibody therapeutics designed to change the way diseases are currently being treated. The objective of the company is to establish a broad pipeline of preclinical and clinical assets which itcan efficiently develop through successive value inflection points. The company's primary focus areas are oncology and infectious disease, including COVID-19. It operates in the U.S. Its current pipelines comprise IM-1021, a fibroblast activation protein (FAP) and and IM-4320.
About CINGW Cingulate Inc.
Cingulate Inc is a clinical-stage biopharmaceutical company utilizing its proprietary precision timed-release drug delivery platform to build and advance a pipeline of next-generation pharmaceutical products designed to improve the lives of patients suffering from frequently diagnosed conditions characterized by burdensome daily dosing regimens and suboptimal treatment outcomes. The company focuses on the treatment of Attention Deficit/Hyperactivity Disorder (ADHD) and anxiety, and identifying and evaluating additional therapeutic areas to use PTR technology to develop future product candidates.